Wyden Continues Investigation Into Big Pharma Tax Practices

Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., today continued his investigation into Big Pharma’s tax practices, and how loopholes in the tax code have allowed multinational companies to further abuse tax havens and avoid paying U.S. taxes on prescription drug sales. Wyden wrote to Bristol Myers Squibb to request information about their […]

Wyden Launches Investigation into Opportunity Zones

Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., today launched an investigation into the Opportunity Zone Program and whether it has delivered on Republican promises to create jobs and drive investment in low-income communities, rather than just create a loophole for wealthy investors to avoid paying taxes. In letters to SkyBridge Capital, Baker […]

Wyden Statement on Taxpayer Advocate Report

MEMORANDUM To: Reporters and Editors From: Ashley Schapitl, Office of Senate Finance Committee Chair Ron Wyden, D-Ore. Date: January 12, 2022 Re: Wyden Statement on Taxpayer Advocate Report _____________________________________________________________________________________ Washington, D.C— Senate Finance Committee Chair Ron Wyden, D-Ore., today released the following statement in response to the National Taxpayer Advocate Report:   “I’ve been sounding […]

Bipartisan Senate Finance Committee Leaders Wyden and Crapo: USTR Must Enforce USMCA to Ensure Benefits for American Workers, Farmers and Businesses

Washington, D.C. – Senate Finance Committee Chairman Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, called for the Biden Administration to use the tough new trade enforcement tools created by the U.S.-Mexico-Canada Agreement (USMCA) to ensure Canada and Mexico live up to their commitments, in a letter today to U.S. Trade Representative Katherine Tai. […]

Wyden Statement on HHS Decision to Reassess Part B Premium Increase

MEMORANDUM To: Reporters and Editors From: Taylor Harvey, Office of Senate Finance Chair Member Ron Wyden, D-Ore. Date: January 10, 2022 Re: Wyden Statement on HHS Decision to Reassess Part B Premium Increase Senate Finance Committee Chair Ron Wyden, D-Ore., today issued a statement after Health and Human Services (HHS) Secretary Xavier Becerra directed the […]

Wyden Supports Biden Administration Action to Help Independent Pharmacies

Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., today issued a statement after the Centers for Medicare & Medicaid Services (CMS) proposed a new rule to address high fees imposed on pharmacies by pharmacy benefit managers (PBMs): “This proposed rule is an important step towards easing the financial strain on thousands of independent […]

Wyden Praises Win for U.S. Dairy Producers in USMCA Dispute Resolution Case

Senate Finance Committee Chairman Ron Wyden, D-Ore., today applauded a win by the U.S. in a challenge to Canada’s barriers to American dairy products. A dispute resolution panel convened under the United States-Mexico-Canada Agreement (USMCA) found that Canada’s use of tariff rate quotas to unfairly restrict U.S. dairy products is inconsistent with its USMCA obligations. […]

Wyden, Crapo Welcome Input on Addressing the Mental Health Care Crisis

Washington, D.C. – Senate Finance Committee Chairman Ron Wyden, D-Ore., and Finance Committee Ranking Member Mike Crapo, R-Idaho, today released submissions responding to the committee’s bipartisan initiative to address barriers to mental health care. “Far too frequently, Americans struggle to access timely, affordable, high-quality behaviorial health care and substance use disorder services— a crisis which […]

Wyden Statement on Aduhelm Price Change

Senate Finance Committee Chair Ron Wyden, D-Ore., today issued a statement after Biogen, the maker of an Alzheimer’s drug called Aduhelm, announced a price decrease for the drug: “This price change highlights the stakes of high cost prescription drugs for seniors and taxpayers,” Wyden. “Despite this price reduction, if Medicare covers Aduhelm, its price would […]